Press Releases

Generex Biotechnology Corporation (www.generex.com) is pleased to announce that the company has signed a contract with EpiVax (https://epivax.com/) to use their computational tools to predict epitopes that can be used to generate peptide vaccines against the nCOV-2019 corona virus using the patented NuGenerex Immuno-Oncology(NGIO - Formerly Antigen Express) Ii-Key technology. EpiVax is a leader in computational vaccinology with expertise in epitope prediction, immune modulation, and dehumaniz

Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular he

Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, today announced the formation of a strategic partnership to advance two bispecific antibodies in key Asian markets including Greater China, Japan, and South Korea. The strategic partnership was formed with Abpro Bio Co. Ltd (“Abpro Bio”) (KOSDAQ: 195990), formerly known as Ugint Co. Ltd. Under this partne

Gilead Sciences, Inc. and Forty Seven, Inc. announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions.

L2P Research LLC, a leading preclinical CRO, today announced that it had completed its acquisition of METIS Research Laboratories headquartered in Ronkonkoma, New York. The Acquisition adds to L2P’s network 5,000 square-foot GLP compliant facility which is focused on providing Radiobinding assays, preclinical toxicology and whole body autoradiograph (QWBA) for innovators of advanced biotherapeutics. METIS Laboratories was founded in 2010 and provides radiotracer services for p

Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform. Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of up to three new ODC candidates. This new collaboration combines Boehringer Ingelheim’s long-term strategy to provide first-

Puma Biotechnology, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The sNDA approval was based on results of the Phase III NALA trial, a randomized controlled trial of ner

CPhI Japan – organised by Informa Markets – announces that the event will be postponed until a new date later in the year after extensive consultation with key stakeholders and consideration of all alternatives. The event, which was due to take place at the Big Sight Exhibition Centre in Tokyo (16-18 March), will be rescheduled due to the increasingly complex travel arrangements many of its attendees are experiencing as a result of COVID-19. The decision was taken after

Pharmaceutics International, Inc. (Pii), a pharmaceutical contract development and manufacturing organization (CDMO), announces the expansion of its aseptic filling capacity and capabilities with the addition of a new, fully robotic filling line. Pii has installed a GENiSYS® R filling machine from Automated Systems of Tacoma, LLC (AST), which processes pre-sterilized, ready-to-fill vials, syringes, and cartridges on a single machine specifically designed for small to medium scal

FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (FDB), a Biologics Contract Development and Manufacturing Organization with experience focused on the development and manufacture of recombinant biopharmaceuticals including proteins, advanced therapies, and monoclonal antibodies, held a ground-breaking ceremony on February 25, 2020 to signal the start of its North Carolina facility expansion project. The 31,778 square foot addition includes the expansion of its cell culture and microbi